Evaluation of the therapeutic efficacy of the drug Cytochrome C in the treatment of asthenia in outpatients (CITRIN study)

Asthenic syndrome occurs in most chronic diseases, and doctors encounter it in outpatient appointments for both somatic and neurological pathologies. Drugs that normalize energy metabolism, have an antioxidant effect and antihypoxic properties are used to treat asthenia.Objective: to investigate the therapeutic efficacy of the drug Cytochrome C in patients with asthenia of various origin in an outpatient setting.Material and methods. The study included 147 outpatients with asthenia who received Cytochrome C 10 mg intramuscularly daily for 10 days. The assessment of the initial level of asthenia manifestations and their changes in dynamics was carried out using the MFI-20 scales, the assessment of daytime sleepiness, the assessment of fatigue (FAS), the severity of symptoms of the disease and the dynamics of the condition according to the doctor and the patient.Results. By the 10th day of therapy, there was a decrease in the severity of asthenia on the MFI-20 scale from 72.2±12.7 to 41.1±12.3 points (p<0.01), including general (by 45%), physical (by 42%) and mental (by 45%) asthenia according to the MFI-20 subscales (p<0.001), improvement in night sleep and reduction in daytime sleepiness on the Epworth scale by 65% – from 9.1±5.6 to 4.6±4.3 points (p<0.001), reduction in severity of fatigue by 29% (p<0.01). The clinically significant improvement lasted until the 30th day of observation, 3 weeks after the end of the therapy. Overall, a significant reduction in asthenia symptoms was observed in 99% of patients on day 10 of therapy and in 96% of cases on day 30.Conclusion. Cytochrome C has been shown to be very effective in patients with asthenia as it reduces all manifestations of asthenia, improves night sleep and reduces daytime sleepiness.